Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-NK-CD19 in Recurrent/Refractory CD19+ ALL
NCT05563545Phase 1Completed
- Sponsor
- Simnova Biotherapeutics
- Start
- Jul 2022
- Primary completion
- Nov 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Anti-CD19 CAR-NK cells in acute lymphoblastic leukemia (ALL), sponsored by Simnova Biotherapeutics. Primary endpoints: Safety of CAR NK-CD19 Cell at 3 months, Cell count of CAR NK-CD19 and 3 more. Started Jul 2022; status: completed.
02
Drugs
Anti-CD19 CAR-NK cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05563545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05563545.